Agile Sciences Receives $428,000 NIH Grant to Evaluate Cystic Fibrosis Therapeutic Application

October 10, 2011

Agile Sciences will collaborate with Dr. Richard Boucher, Director of the Cystic Fibrosis Center at the University of North Carolina, Chapel Hill

Raleigh, NC (PRWEB) October 10, 2011

The National Institutes of Health (NIH) has awarded Agile Sciences a Phase I STTR Grant to evaluate the efficacy of Agile Sciences̢ proprietary Agilyte̢Ң anti-biofilm molecules for treating lung infections of cystic fibrosis patients. The molecules will be tested in a new model of chronic lung infection developed in the lab of Dr. Richard Boucher, Kenan Professor of Medicine and Director of the Cystic Fibrosis Center at UNC Chapel Hill.

Earlier this year, Agile Sciences received a $75,000 grant from the Cystic Fibrosis Foundation) that funded proof-of-concept studies to support the NIH application.

Dr. Eva Garland, Agile Sciencesâ VP of Research and Development, stated, âœIt is particularly gratifying to receive this NIH award so soon after successfully completing the preliminary studies funded by the CF Foundation. This grant allows us to continue our momentum in developing a CF therapeutic by testing our molecules in a more sophisticated model.â

âœWe are appreciative of the opportunity to collaborate with Dr. Boucher, who is a world-renown leader in cystic fibrosis research,â noted Agile Sciencesâ co-founder, Dr. Christian Melander.

Dr. Boucher commented, âœThis exciting new technology has the potential to deal with a truly immense clinical problem in CF, i.e. chronic infection with drug resistant biofilm forms of bacteria.â

This NIH STTR project will begin immediately and continue through August 31, 2012.

About Agile Sciences:

Agile Sciences is headquartered on North Carolina State University’s Centennial Campus. The company was founded in 2007 to provide commercial solutions to those industries plagued by the effects of biofilms. The company’s proprietary Agilyteâ“¢ compounds have been shown to be effective in dispersing biofilms and overcoming bacterial resistance mechanisms. For additional information, please visit: http://www.agilesci.com.


For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/10/prweb8854413.htm

Source: prweb

comments powered by Disqus